MX2022010520A - Macrociclos peptidicos contra acinetobacter baumannii. - Google Patents

Macrociclos peptidicos contra acinetobacter baumannii.

Info

Publication number
MX2022010520A
MX2022010520A MX2022010520A MX2022010520A MX2022010520A MX 2022010520 A MX2022010520 A MX 2022010520A MX 2022010520 A MX2022010520 A MX 2022010520A MX 2022010520 A MX2022010520 A MX 2022010520A MX 2022010520 A MX2022010520 A MX 2022010520A
Authority
MX
Mexico
Prior art keywords
sup
acinetobacter baumannii
against acinetobacter
peptide macrocycles
macrocycles against
Prior art date
Application number
MX2022010520A
Other languages
English (en)
Inventor
Hans Hilpert
Hong Shen
taishan Hu
Sabine Kolczewski
Theodor Stoll
Konrad Bleicher
Bernhard Fasching
Alexander Alanine
Julien Beignet
Dwight Macdonald
Stephen Jackson
Carsten Kroll
Adrian Schaeublin
Helmut Thomas
Amal Wahhab
Claudia Zampaloni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022010520A publication Critical patent/MX2022010520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) (ver Fórmula) (I) en donde de X1 a X8 y de R1 a R8 son tal como se definen en el presente documento, así como sales farmacéuticamente aceptables de los mismos. Además, la presente invención se refiere a la fabricación de compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos para el tratamiento de enfermedades e infecciones causadas por Acinetobacter baumannii.
MX2022010520A 2015-10-27 2018-04-26 Macrociclos peptidicos contra acinetobacter baumannii. MX2022010520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15191743 2015-10-27
CN2016100125 2016-09-26

Publications (1)

Publication Number Publication Date
MX2022010520A true MX2022010520A (es) 2022-09-19

Family

ID=57200005

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005236A MX2018005236A (es) 2015-10-27 2016-10-24 Macrociclos peptidicos contra acinetobacter baumannii.
MX2022010520A MX2022010520A (es) 2015-10-27 2018-04-26 Macrociclos peptidicos contra acinetobacter baumannii.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018005236A MX2018005236A (es) 2015-10-27 2016-10-24 Macrociclos peptidicos contra acinetobacter baumannii.

Country Status (26)

Country Link
US (3) US10030047B2 (es)
EP (1) EP3368544B1 (es)
JP (2) JP7286317B2 (es)
KR (1) KR102701379B1 (es)
CN (1) CN108350028B (es)
AU (1) AU2016347456B2 (es)
CL (1) CL2018000978A1 (es)
CO (1) CO2017013708A2 (es)
CR (1) CR20180232A (es)
DK (1) DK3368544T3 (es)
ES (1) ES2811911T3 (es)
HR (1) HRP20201273T1 (es)
HU (1) HUE050053T2 (es)
IL (1) IL258060B (es)
MX (2) MX2018005236A (es)
MY (1) MY193014A (es)
PE (1) PE20180796A1 (es)
PH (1) PH12018500904A1 (es)
PL (1) PL3368544T3 (es)
PT (1) PT3368544T (es)
RS (1) RS60662B1 (es)
RU (1) RU2729609C2 (es)
SI (1) SI3368544T1 (es)
TW (1) TWI720042B (es)
UA (1) UA124303C2 (es)
WO (1) WO2017072062A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101984151B1 (ko) * 2014-08-13 2019-05-30 후아웨이 테크놀러지 컴퍼니 리미티드 Ｆｂｍｃ 신호 전송 방법, 수신 방법, 전송기 및 수신기
RU2729609C2 (ru) 2015-10-27 2020-08-11 Ф. Хоффманн-Ля Рош Аг Пептидные макроциклы против acinetobacter baumannii
KR102390246B1 (ko) 2016-12-21 2022-04-22 에프. 호프만-라 로슈 아게 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
EP3559249A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of antibodies
EP3388444A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) * 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
JP2022513851A (ja) * 2018-12-17 2022-02-09 エフ．ホフマン－ラ ロシュ アーゲー 抗菌剤としてのイミダゾピラジン誘導体
WO2020182648A1 (en) 2019-03-08 2020-09-17 F. Hoffmann-La Roche Ag Novel imidazole-pyrazole derivatives
JP7715715B2 (ja) 2020-01-22 2025-07-30 エフ． ホフマン－ラ ロシュ アーゲー 新規複素環式化合物
WO2021219578A1 (en) 2020-04-29 2021-11-04 F. Hoffmann-La Roche Ag Antibacterial 8-phenylamino-3-(pyrazol-4-yl)imidazo[1,2-a]pyrazine derivatives
WO2021244997A1 (en) 2020-06-01 2021-12-09 F. Hoffmann-La Roche Ag Novel imidazopyrazne derivatives
CN115667264A (zh) 2020-06-08 2023-01-31 豪夫迈·罗氏有限公司 新型咪唑并-吡嗪衍生物
CN115916784A (zh) 2020-06-09 2023-04-04 豪夫迈·罗氏有限公司 新型咪唑并吡嗪衍生物
CN115989225A (zh) 2020-08-31 2023-04-18 豪夫迈·罗氏有限公司 作为抗菌药物的咪唑-吡唑衍生物
WO2022049011A1 (en) 2020-09-01 2022-03-10 F. Hoffmann-La Roche Ag Imidazole-pyrazole derivatives with anti-bacterial properties
WO2022049272A1 (en) 2020-09-07 2022-03-10 F. Hoffmann-La Roche Ag Novel heterocyclic antibiotics
JP2024506021A (ja) 2021-02-07 2024-02-08 エフ． ホフマン－ラ ロシュ アーゲー 新規ヘテロアリール置換イミダゾール誘導体
EP4367102A1 (en) 2021-07-06 2024-05-15 F. Hoffmann-La Roche AG Quaternary ammonium cation substituted compounds for the treatment of bacterial infections
CN118119609A (zh) 2021-07-15 2024-05-31 豪夫迈·罗氏有限公司 咪唑衍生物及其作为抗生素的用途
WO2023161316A1 (en) 2022-02-25 2023-08-31 F. Hoffmann-La Roche Ag Zwitterionic antibacterial compounds
CN119677765A (zh) * 2022-08-09 2025-03-21 豪夫迈·罗氏有限公司 用于制造抗生素大环肽的方法
WO2025067477A1 (zh) * 2023-09-27 2025-04-03 武汉人福创新药物研发中心有限公司 抗鲍曼不动杆菌的环肽及其应用
CN120424159A (zh) * 2024-02-02 2025-08-05 武汉人福创新药物研发中心有限公司 抗鲍曼不动杆菌的含羧酸取代的环肽及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660832B1 (en) * 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
DE10234422A1 (de) 2002-07-29 2004-02-12 Bayer Ag Antibakterielle Ester-Makrozyklen
DE60310916T2 (de) 2002-08-23 2007-11-15 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
RU2311415C2 (ru) * 2002-08-23 2007-11-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
EP1633774B1 (en) * 2003-06-18 2010-02-17 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1498422A1 (de) 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
EP2319859B1 (en) 2003-07-31 2013-03-27 Tranzyme Pharma Inc. Spatially-defined macrocyclic compounds useful for drug discovery
WO2005012332A1 (en) 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
JP2008502583A (ja) 2003-10-01 2008-01-31 バイエル・ヘルスケア・アクチェンゲゼルシャフト 抗細菌性アミド大員環
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
DE102004025731A1 (de) * 2004-05-26 2005-12-15 Bayer Healthcare Ag Antibakterielle Amid-Makrozyklen III
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CN101107264A (zh) 2005-01-17 2008-01-16 捷瑞尼股份公司 C5a受体拮抗剂
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
EP2118091B1 (en) 2007-02-08 2015-04-15 Janssen Sciences Ireland UC Pyrimidine substituted macrocyclic hcv inhibitors
DE112009000300T5 (de) 2008-02-08 2011-01-20 Aileron Therapeutics, Inc., Cambridge Therapeutische Peptidomimetische Makrocyclen
WO2010022249A2 (en) 2008-08-20 2010-02-25 Ensemble Discovery Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
WO2011050270A2 (en) 2009-10-23 2011-04-28 Tranzyme Pharma, Inc. Macrocyclic inhibitors of serine protease enzymes
WO2011053821A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
WO2013033645A1 (en) 2011-08-31 2013-03-07 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
CN103387601B (zh) 2012-05-11 2017-01-11 南开大学 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
JP6437443B2 (ja) 2012-11-21 2018-12-12 アールキューエックス ファーマシューティカルズ，インク． 大環状広域抗生物質
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
EP3174852B1 (en) 2014-07-30 2018-07-18 Abac Therapeutics, S.L. Arylhydrazides containing a 2-pyridone moiety as selective antibacterial agents
RU2729609C2 (ru) * 2015-10-27 2020-08-11 Ф. Хоффманн-Ля Рош Аг Пептидные макроциклы против acinetobacter baumannii
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Also Published As

Publication number Publication date
AU2016347456B2 (en) 2018-12-13
EP3368544B1 (en) 2020-06-17
PE20180796A1 (es) 2018-05-09
JP7286317B2 (ja) 2023-06-05
US20180362578A1 (en) 2018-12-20
NZ738307A (en) 2024-02-23
EP3368544A1 (en) 2018-09-05
MY193014A (en) 2022-09-22
AU2016347456A1 (en) 2018-01-18
TWI720042B (zh) 2021-03-01
CN108350028A (zh) 2018-07-31
CA2992926A1 (en) 2017-05-04
PH12018500904A1 (en) 2018-11-05
TW201718565A (zh) 2017-06-01
US11098080B2 (en) 2021-08-24
US20220411468A1 (en) 2022-12-29
JP2018535960A (ja) 2018-12-06
IL258060B (en) 2021-05-31
PL3368544T3 (pl) 2020-11-16
US12012466B2 (en) 2024-06-18
RU2729609C2 (ru) 2020-08-11
CN108350028B (zh) 2021-12-07
JP2022024009A (ja) 2022-02-08
US10030047B2 (en) 2018-07-24
KR20180063138A (ko) 2018-06-11
HK1258443A1 (zh) 2019-11-15
RU2018113426A3 (es) 2020-01-31
UA124303C2 (uk) 2021-08-25
SI3368544T1 (sl) 2020-10-30
CO2017013708A2 (es) 2018-03-20
HRP20201273T1 (hr) 2020-11-13
DK3368544T3 (da) 2020-08-24
PT3368544T (pt) 2020-08-20
KR102701379B1 (ko) 2024-09-02
MX2018005236A (es) 2018-08-15
CR20180232A (es) 2018-05-31
US20170233437A1 (en) 2017-08-17
IL258060A (en) 2018-05-31
HUE050053T2 (hu) 2020-11-30
RU2018113426A (ru) 2019-11-28
RS60662B1 (sr) 2020-09-30
CL2018000978A1 (es) 2018-08-24
WO2017072062A1 (en) 2017-05-04
ES2811911T3 (es) 2021-03-15

Similar Documents

Publication Publication Date Title
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12020551762A1 (en) Peptide macrocycles against acinetobacter baumannii
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MY174284A (en) Compounds for treating spinal muscular atrophy
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
NZ708593A (en) Novel pyrazole derivative
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
EP4252848A3 (en) Oxysterols and methods of use thereof
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
PH12018500378A1 (en) Novel annelated phenoxyacetamides
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
EA201990656A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7